GLP-1 Medications for Obesity
Clinical obesity (BMI 30+). Primary indication for GLP-1 medications. Obesity affects 42% of US adults, and GLP-1 medications offer a clinically proven treatment option.
Prevalence
42% of US adults
Recommended Medications
2
Treatment Type
GLP-1 Agonist
How GLP-1 Medications Help with Obesity
Primary indication for GLP-1 medications. For patients with obesity, GLP-1 medications address the underlying metabolic dysfunction that makes weight management difficult. Clinical trials have consistently shown that GLP-1 treatment produces significant improvements in both weight and condition-specific outcomes.
Recommended GLP-1 Medications for Obesity
Based on clinical evidence, the following GLP-1 medications are recommended for patients with obesity:
Semaglutide
Wegovy / Ozempic
Tirzepatide
Zepbound / Mounjaro
Detailed Medication Guides for Obesity
Obesity & GLP-1 FAQ
Can GLP-1 medications help with obesity?
Yes. Primary indication for GLP-1 medications. Clinical evidence supports the use of GLP-1 medications like semaglutide and tirzepatide for patients with obesity.
Which GLP-1 medication is best for obesity?
Semaglutide is often the first-line recommendation for obesity due to its strong clinical evidence. Your provider will evaluate your specific situation to determine the best option.
How much weight can I lose with GLP-1 if I have obesity?
Weight loss results are generally comparable to clinical trial averages (15-22% of body weight), though individual results vary based on the severity of obesity and other health factors.
How prevalent is obesity?
Obesity affects 42% of US adults. GLP-1 medications represent a significant treatment advancement for patients dealing with this condition alongside excess weight.